MedPath

To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

Phase 3
Conditions
Chorioretinitis
Interventions
Registration Number
NCT00372294
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin \& Dexamethasone.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients with Toxoplasmic chorioretinitis
  • Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III
  • No allergic history to the used drugs
  • No any other diseases
Exclusion Criteria
  • Any allergic reaction to the used medications
  • One eyed patients
  • Partially treated patients

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1pyrimethamine-sulfadiazine + prednisoloneClassic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
2Clindamycin+DexamethasoneIntravitreal Clindamycin \& Dexamethasone
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ophthalmic Research Center

🇮🇷

Tehran, Iran, Islamic Republic of

Ophthalmic Research Center
🇮🇷Tehran, Iran, Islamic Republic of

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.